Gabapentin
Product Images NDC 68788-8641

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Gabapentin (NDC 68788-8641). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Preferred Pharmaceuticals Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure 1 (Ab1e0185 B802 4cf2 A5d4 B71f27f1dcb0 00)

A formula diagram illustrating the calculation of creatinine clearance (CLCr), showing the variables age in years, weight in kilograms, serum creatinine in mg/dL, and an adjustment factor of 0.85 for female patients.*

FDA Label Image

Gabapentin Tablets 600mg (Containerlabel 600mg Strides)

Label for Gabapentin Tablets 600mg by Preferred Pharmaceuticals Inc. The label indicates the drug is a generic for Neurontin, with each film-coated tablet containing 600mg of Gabapentin. It includes storage instructions and cautions, manufacturer information (ACI HealthCare Limited), and directions for use in English and Spanish. The label has a barcode and a QR code.*

FDA Label Image

Chem Structure (D45f499b 8612 479e 8dd2 4fe28b1f5f9c 01)

Chemical structure of gabapentin, showing a cyclohexane ring attached to an aminomethyl and a carboxymethyl group.*

FDA Label Image

Figure01 (D45f499b 8612 479e 8dd2 4fe28b1f5f9c 02)

A line graph showing mean pain scores over an 8-week period comparing placebo and Gabapentin at 3600 mg/day. The x-axis represents weeks from baseline to week 8, with labeled 4-week dose titration and fixed dose periods. Gabapentin shows a decreasing pain score trend, while placebo remains relatively stable.*

FDA Label Image

Figure02 (D45f499b 8612 479e 8dd2 4fe28b1f5f9c 03)

A line chart depicting mean pain scores over a 7-week period, including a 3-week dose titration period followed by a 4-week fixed dose period. The chart compares placebo, Gabapentin 1800 mg/day, and Gabapentin 2400 mg/day, showing decreasing pain scores for both Gabapentin doses versus placebo over time.*

FDA Label Image

Figure03 (D45f499b 8612 479e 8dd2 4fe28b1f5f9c 04)

Bar chart titled 'Proportion of Responders (patients with ≥ 50% reduction in pain score) at Endpoint: Controlled PHN Studies.' It compares the percentage of responders for two studies with placebo (PBO) and Gabapentin (GBP) at different doses. Study 1 shows 12% for PBO and 29% for GBP 3600. Study 2 shows 14% for PBO, 32% for GBP 1800, and 34% for GBP 2400. Statistical significance is indicated with p-values less than 0.01 and 0.001.*

FDA Label Image

Figure4 (D45f499b 8612 479e 8dd2 4fe28b1f5f9c 05)

A scatter plot comparing percentage difference versus daily dose in milligrams for Gabapentin across three studies labeled a, b, and c. The x-axis shows daily doses from 600 to 1800 mg, while the y-axis shows percentage difference from 2% to 22%. Each study is represented by differently shaded squares, depicting dose-response relationships.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.